- All
- About MAA News Items
- Annual Conference News Items
- Art With Heart News Items
- Get Involved News Items
- Health Professionals News Items
- Living with MG News Items
- MG Awareness Month News Items
- Patient Tool Kit
- Policy Makers News Items
- Understanding MG News Items
Conversations continue for access to new treatments
We appreciate that it has been a couple of months since the Pharmaceutical Benefits Advisory Committee (PBAC) recommended that 4 new treatments for AChR+ generalised MG patients be listed on the Pharmaceutical Benefits Scheme (PBS)… In this time, the MAA has continued conversations with clinicians, government, and industry stakeholders to make sure we understand the progress…
Success: Four new treatment options recommended for MG patients in Australia!
The Pharmaceutical Benefits Advisory Committee (PBAC) has published the outcomes from their March 2025 meeting. PBAC has recommended that all 4 new treatments for MG patients be listed on the Pharmaceutical Benefits Scheme (PBS). This is wonderful news for our patient community in Australia and it shows that our submissions and engagement with the assessment process were impactful…
Proudly Supporting MGBase
The bold concept to have a physician captured, longitudinal data base reflecting real time evidence about treatment benefits for people with Myasthenia Gravis was first presented to the Myasthenia patient group in December 2016. The Myasthenia community committed to raising $40,000 to support this work. The project was known as eNID. At the 2017 Conference…
Rare Diseases Day 2025!
Today is our special day as the world recognises people with a rare disease such as Myasthenia. The MAA share the 2025 logo with you and perhaps you will share this email with others. For the rare disease sector there are challenges to gaining comprehensive and equitable care and to being understood. Celebrating today and…
Framing the PBAC Submissions and why your participation has been impactful.
Thank you to everyone who joined us for the webinar about new treatments and Pharmaceutical Benefits Advisory Committee (PBAC) submissions, and to all of you who made a submission and shared your lived experience and treatment preferences as part of the PBAC process. The PBAC meeting takes place in March, and we will know the…
Last chance to make your submission to PBAC!
This is a final reminder that the patient/consumer submissions to PBAC (Pharmaceutical Benefits Advisory Committee) close at 11pm on Wednesday 29 January 2025! Make your submission(s) via the online form here. These submissions will contribute to the PBAC meeting in March where they will consider 4 new treatments for Myasthenia Gravis (MG) being available and accessible in…
Time for your Submission to PBAC
A big thank you to everyone who attended and participated in our webinar on 15 January. For those who registered but couldn’t join at the time, please check your emails for a link to the recording. If you haven’t done so already, now is the time to make your submission to PBAC about new treatments for Myasthenia…
Last chance! MAA webinar registrations are closing
Don’t hesitate for one more minute! Register here for the Myasthenia Alliance Australia (MAA) webinar to learn about new treatments for generalised Myasthenia Gravis. You may be offered new treatments in the future and this webinar will help you understand what these treatments are and how they may benefit you. The webinar will be held at 5:30pm (AEDT)/4.30pm (AEST) on Wednesday 15…
Register NOW for the MAA webinar on new treatments for Myasthenia!
It is a new year and we have a once in a generation opportunity for new treatments for Myasthenia Gravis! The Pharmaceutical Benefits Advisory Committee (PBAC) will assess 4 new treatments for generalised Myasthenia Gravis (gMG) at its meeting in March 2025. You can make a personal submission by 29 January 2025 highlighting your lived experience as a Myasthenia patient to add…